Prospective, phase IIa, multicenter, open, non-controlled efficacy and tolerability of first-line therapy as a single agent eribulin in patients with HER2 negative metastatic breast cancer previously treated with taxanes

Trial Profile

Prospective, phase IIa, multicenter, open, non-controlled efficacy and tolerability of first-line therapy as a single agent eribulin in patients with HER2 negative metastatic breast cancer previously treated with taxanes

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms MERIBEL
  • Most Recent Events

    • 11 Oct 2016 Results assessing efficacy and safety of Eribulin as first line therapy presented at the 41st European Society for Medical Oncology Congress
    • 29 Sep 2016 According to Eisai media release, subanalyses from this study will be presented at the European Society for Medical Oncology (ESMO) Congress.
    • 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top